Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III …

DF Hanley, K Lane, N McBee, W Ziai, S Tuhrim… - The Lancet, 2017 - thelancet.com
Background Intraventricular haemorrhage is a subtype of intracerebral haemorrhage, with
50% mortality and serious disability for survivors. We aimed to test whether attempting to …

A multicenter, randomized, double-blinded, placebo-controlled phase III study of Clot Lysis Evaluation of Accelerated Resolution of Intraventricular Hemorrhage …

WC Ziai, S Tuhrim, K Lane, N McBee… - … Journal of Stroke, 2014 - journals.sagepub.com
Background In adults, intraventricular thrombolytic therapy with recombinant tissue
plasminogen activator (rtPA) facilitates resolution of intraventricular haemorrhage (IVH) …

Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study

X Huang, BK Cheripelli, SM Lloyd, D Kalladka… - The Lancet …, 2015 - thelancet.com
Background In most countries, alteplase given within 4· 5 h of onset is the only approved
medical treatment for acute ischaemic stroke. The newer thrombolytic drug tenecteplase has …

European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke

E Berge, W Whiteley, H Audebert… - European stroke …, 2021 - journals.sagepub.com
Intravenous thrombolysis is the only approved systemic reperfusion treatment for patients
with acute ischaemic stroke. These European Stroke Organisation (ESO) guidelines provide …

Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised …

BK Menon, BH Buck, N Singh, Y Deschaintre… - The Lancet, 2022 - thelancet.com
Background Intravenous thrombolysis with alteplase bolus followed by infusion is a global
standard of care for patients with acute ischaemic stroke. We aimed to determine whether …

Preliminary report of the clot lysis evaluating accelerated resolution of intraventricular hemorrhage (CLEAR-IVH) clinical trial

T Morgan, I Awad, P Keyl, K Lane, D Hanley - Cerebral Hemorrhage, 2008 - Springer
Introduction Brain hemorrhage is the most frequent fatal form of stroke and has the highest
level of morbidity of any stroke subtype. For patients with both intracerebral hemorrhage and …

Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open …

A Bivard, H Zhao, L Churilov, BCV Campbell… - The Lancet …, 2022 - thelancet.com
Summary Background Mobile stroke units (MSUs) equipped with a CT scanner reduce time
to thrombolytic treatment and improve patient outcomes. We tested the hypothesis that …

Extending the time window for intravenous thrombolysis in acute ischemic stroke using magnetic resonance imaging-based patient selection

P Ringleb, M Bendszus, E Bluhmki… - … Journal of Stroke, 2019 - journals.sagepub.com
Background Intravenous thrombolysis with alteplase within a time window up to 4.5 h is the
only approved pharmacological treatment for acute ischemic stroke. We studied whether …

Off‐label intravenous thrombolysis in acute stroke

M Guillan, A Alonso‐Canovas… - European Journal of …, 2012 - Wiley Online Library
Background and purpose: Therapy for stroke with intravenous tissue plasminogen activator
(IV‐tPA) is hampered by tight licensing restrictions; some of them have been discussed in …

Long-term survival after intravenous thrombolysis for ischemic stroke: a propensity score-matched cohort with up to 10-year follow-up

W Muruet, A Rudd, CDA Wolfe, A Douiri - Stroke, 2018 - Am Heart Assoc
Background and Purpose—Intravenous thrombolysis with alteplase is one of the few
approved treatments for acute ischemic stroke; nevertheless, little is known about its long …